BioSpace News Archive

Q 2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Collaborates with University of Texas Medical Branch to Help Accelerate Development of COVID-19 Vaccines

Novan, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of 18,604,652 shares of its common stock at an effective purchase price of $0.43 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut

Life Sciences Investor Forum announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world.

SPI Pharma has announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald, and Mannogem Onyx.

eTheRNA Immunotherapies nv announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started.

OncoQuest Inc. announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the Company’s lead investigational drug in frontline ovarian cancer.

Parallax Acquired Antigen And Antibodies Of COVID-19 Being Integrated Into Its Patented And FDA Approved Target Diagnostics Test Platform

OpSens Inc., a cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, provided a business update in light of recent action taken by the province of Quebec regarding COVID-19.

Proceeds to Support Clinical Development of Immuno-oncology Therapeutic APX005M and Advancement of New Immunotherapeutic Antibodies into Clinical Evaluation